title: Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations.
authors: Division of Pediatric Neurology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA 90095-1752, USA. wshields@mednet.ucla.edu
authors: W D
authors: WD
authors: Shields
authors: J M
authors: JM
authors: Pellock
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000266:history* / Q000627:therapeutic use*; D004828:Epilepsies, Partial / Q000188:drug therapy*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007223:Infant; D007494:Ireland; D013036:Spasms, Infantile / Q000188:drug therapy*; D006113:United Kingdom; D020888:Vigabatrin / Q000266:history* / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin